Radicait

Based in the US, Radicait is a health technology company focused on developing innovative medical imaging solutions, specifically through the generation of synthetic PET images derived from CT scans using advanced artificial intelligence techniques. Radicait specializes in creating advanced imaging technologies for the healthcare sector. Founded in Boston, US, the company is led by a team with extensive experience in the field. On October 14, 2025, Radicait successfully raised USD 1.

7 mn in pre-seed funding, led by Frontline and supported by other investors including Gurtin Ventures and Techstars. The funding represents the total amount raised by the company to date. RADiCAIT's core offering centers on the development of innovative medical imaging solutions, specifically the generation of synthetic PET images derived from CT scans through advanced artificial intelligence. This approach provides a groundbreaking alternative to traditional nuclear medicine techniques, which often involve the use of radioactive tracers and are limited by logistical complexities and patient discomfort.

By leveraging deep-learning algorithms, RADiCAIT facilitates the creation of synthetic PET-CT images, enhancing accessibility and efficiency in diagnostic imaging, particularly in the fields of oncology, cardiology, and neurology. Their target client base includes major healthcare institutions and radiology centers that require safe and effective imaging solutions. The company primarily serves markets in North America, Europe, and select regions in Asia, positioning its technology as a crucial advancement in radiology. The revenue model for RADiCAIT is structured around partnerships with healthcare providers, academic institutions, and technology firms engaged in radiology.

The company’s business transactions typically involve collaborations that integrate its synthetic PET imaging technology into existing healthcare frameworks, streamlining imaging procedures and enhancing diagnostic capabilities. Clients may engage with RADiCAIT through long-term partnerships, which could encompass licensing agreements or collaborative research initiatives to implement their AI-driven imaging solutions. These arrangements facilitate the deployment of RADiCAIT's technology, maximizing its utility in clinical settings while supporting the company’s goal of improving patient outcomes. Pricing structures are customized based on the specific needs and scale of the healthcare providers involved, ensuring that the services align with operational demands and patient care objectives.

In October 2025, Radicait raised USD 1. 7 mn in pre-seed funding led by Frontline, which will be utilized to further develop its artificial intelligence imaging technology. The company plans to introduce new products that enhance its imaging solutions and is targeting expansion into additional markets in North America and Europe by 2026, aiming to increase its global presence in the healthcare technology sector.